We previously demonstrated that STAT1H tumors overexpressing the IFN/STAT1 pathway are resistant to Dox treatment and that constitutive expression of this pathway is predictive for response to adjuvant chemotherapy in patients with breast cancer [18], [25]. The gene discussed is STAT1; the disease is breast cancer.